Too often contrarianism is confused and substituted for critical thinking. However to read anything about any new product without contrasting Astro turfing or propaganda is naive

C.R.C. has received research support from the American Foundation for Suicide Prevention, Assurex Health, August Busch IV Foundation, Barnes-Jewish Hospital Foundation, LivaNova, National Institute of Mental Health, and the Taylor Family Institute for Innovative Psychiatric Research. He has also consulted for LivaNova. A.J.R. has received consulting fees from Beckley Psytech Inc., Better Up, Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson & Johnson (Janssen), LivaNova, MindStreet, Inc., Neurocrine Biosciences Inc., and Otsuka-US; speaking fees from LivaNova and Johnson & Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press, and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptomatology and its derivatives). He is also named co-inventor on 2 patents: US Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, and Wilson AS; and US Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, and Paddock S. S.T.A. is a consultant to Genomind, Janssen, LivaNova, Neuronetics, and Sage Therapeutics and has received research support from Compass Pathways and Neuronetics. M.T.B. is a former employee of and current consultant for LivaNova. C.G. is an employee of LivaNova and holds LivaNova stock. M.S.G. has received research support from Abbott, LivaNova, Neurolief, and Magnus Medical. He consults for Abbott, Hospital Corp of America, the Jacob Zabara Family Foundation, Neurolief, and Sooma. P.R.-P. is a consultant for LivaNova, Janssen Pharmaceuticals, Motif Neurotech, and Abbott Neuromodulation. R.M.A. has received research support from LivaNova, Compass Pathways, MindMed, Transcend Therapeutics, Wave Neuroscience, Magnus Medical, Janssen, Kernel, Usona Institute, and Alto Neuroscience. She has served on the advisory board for LivaNova and consulted for Starfish Neuroscience. Z.N. is a consultant to LivaNova, Magnus Medical, and Motif and has also received research support from LivaNova. C.L.K. has no conflicts to disclose. J.Z. receives research support from Boehringer Ingelheim, Compass Pathways, Hoffman-LaRoche, Johnson & Johnson (Janssen), LivaNova, Otsuka, Neurocrine Bioscience, and Sage Therapeutics and has received consulting fees from Alfasigma USA and Johnson & Johnson (Janssen). D.L.D. receives payment for clinical services for a former research patient from LivaNova, is a speaker for Janssen (esketamine nasal spray), and conducts forensic consultations, independent medical evaluations, and legal testimony for various firms. J.Q. has clinical research support from LivaNova, Neumora Therapeutics, and Johnson and Johnson; has been a consultant for LivaNova; and receives copyrights from Artmed Editora, Artmed Panamericana, and Elsevier/Academic Press. Y.S. has no conflicts of interest to declare. W.D. has received research support from Abbott Nutrition, AbbVie, Acadia, Akili, Alkermes, Allergan, Alto Neuroscience, AriBio, Axsome, Biohaven, Bionomics, Clexio, Compass Pathways, Corcept, Corium, Denovo Biopharma, Emalex, GlaxoSmithKline Biologicals, Hoffmann-LaRoche, Intra-Cellular, Ironshore, Janssen, Jazz, LivaNova, Lumos, Merck Sharp & Dohme, Neurocrine Biosciences, NRx, Otsuka, Sage Therapeutics, Sanofi Pasteur, Shire, Sirtsei, Spark Neuro, Sumitomo, Sunovion, and Supernus. He is on a speakers bureau or advisory board or is a consultant for Abbott Neuromodulation, Corium, and LivaNova. B.J.M. received research support from NIH, NSF, Wellcome Leap, PCORI, Health Rhythms, LivaNova, Compass, and Abbott and consulting fees from Inside Edge, VML, Atheneum, Guidepoint, Kx Advisors, and S2N Health. M.S. states the following disclosures: LivaNova, Compass Pathfinder Limited, Neurocrine Biosciences, Neumora Therapeutics, Lilly, and Eisai. G.A. receives research support from AbbVie, Accera, Axsome, Axovant, Biogen, Eisai, Eli Lily, Neurotrope, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Sage, Suven, and TransTech and is on the speakers bureau of and a consultant for AbbVie, Acadia, Alkermes, Axsome, Biogen, Janssen, Idorsia, Lundbeck, Myriad, Neurocrine, Nestle, Otsuka, Sage, Sunovion, Teva, and Takeda. L.M. has received research funding administered through Stony Brook University from Janssen Pharmaceuticals (developer of esketamine) to conduct clinical trials with esketamine, received research funding administered through Stony Brook University from LivaNova (the developer of vagus nerve stimulation [VNS] technology) to conduct clinical trials with VNS, and served as a consultant and member of the Spravato speakers bureau for Janssen Pharmaceuticals. Q.T. is an employee of LivaNova. C.F.Z. served on the Scientific Advisory Board of Sage Therapeutics and had equity in the company. He has received royalties from Oxford University Press and research support from the Taylor Family Institute for Innovative Psychiatric Research and the Bantly Foundation. M.M. discloses the following over the last 24 months: (1) Received research support from Alto, Boehringer Ingelheim, LivaNova, Janssen, Merck, Neurocrine, Otsuka, SAGE, PCORI, and NIH/NIMH. All clinical trial payments were made to the University of Alabama at Birmingham. (2) Served as a paid consultant for the CME Institute, NuSachi Labs, PharmaTher, Residents Medical, Tactical Mind Solutions, and the University of Missouri. (3) Received royalties from Springer Nature for textbooks published. M.B. has the following disclosures to declare: AbbVie, Intra-Cellular, Axsome, Janssen, and Teva. He is also a consultant for LivaNova. C.C. has received research support for conducting clinical trials from AFSP, Clexio, ATAI, and Janssen and consulting fees from Compass Therapeutics and Boehringer. J.I.B. receives research support from Teva Pharmaceutical Industries Ltd, Intra-Cellular Therapeutics, J&J Innovative Medicine, and Relmada Therapeutics for clinical trials, administered through the Southern Illinois University School of Medicine. He has received research support from Janssen Research and Development to conduct clinical trials with esketamine, which are also administered through the Southern Illinois University School of Medicine. H.B. has no conflicts to disclose. J.W. is a former employee of LivaNova and holds LivaNova stock. O.S. is an employee of LivaNova and holds LivaNova stock. Y.-C.(L.)L. is an employee of LivaNova and holds LivaNova stock. R.H.M.-W. reports acting as TSC chair for the NIHR HTA-funded SNAPPER trial and DMC chair for the EU-funded PReDicT study. He is Director of Education for the British Association for Psychopharmacology, receives support for meetings via Janssen-Cilag, and receives payments/consultation fees from LivaNova, Janssen-Cilag, Sage Therapeutics, P1Vital, Takeda, and Lundbeck. R.S.M. has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, NeuraWell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, and Atai Life Sciences. H.A.S. serves as a scientific advisor and receives consulting fees from Cerebral Therapeutics, Holmusk Technologies, LivaNova, MECTA Corporation, NeuroInsights, Neurolief, Neuronetics, Parow Entheobiosciences, and SigmaStim; receives honoraria and royalties from Elsevier and Oxford University Press; is the inventor of nonremunerative US patents for focal electrically administered seizure therapy, titration in the current domain in electroconvulsive therapy (ECT), and the adjustment of current in ECT devices, each held by the SigmaStim Corporation; and is also the originator of magnetic seizure therapy.

The statistical analyses that are reported in the article will be shared upon reasonable request to the corresponding author. The raw data are not publicly available.

It doesnt matter if they paid for it, if the results end up being true. What I am looking for is criticism of the methods that invalidate the results. Are there any?

Counter point, "fat makes you fat," "sugar is necessary for a good diet," "fluoride in drinking water improves tooth health," "leaded gasoline is harmless," "leaded paint is safe," etc. Many of these were held "scientifically true" for years and had plenty of "peer-reviewed" science behind that assertion.

Except it wasn't really peer-reviewed. And it was never scientifically proven. Despite the hundreds of research papers that all "passed" peer review.

That's why researchers now have to declare their financial sponsorships in honest science journals, because it automatically means whatever results they're claiming should not be trusted until peers without any financial incentive review the findings. This claim has not been reviewed in that way, so this assertion has the same value as a random lemmy comment.

Only one way to find out...